Medicare physician reimbursement and extension of telehealth flexibilities are two of the ACR’s top legislative priorities as Congress approaches the lame duck session. With physicians facing a 2.8% cut under the 2025 Medicare Physician Fee Schedule proposed rule and telehealth flexibilities set to expire at the end of this year, Congress must hear from the…
Congressional Action Needed to Maintain Medicare’s Extended Telehealth Services
Medicare’s extended telehealth services will expire at the end of the year unless Congress acts to continue them. Make sure your legislators know how a failure to act will harm patient access to care.
How the ACR Helps with Reimbursement, Utilization Management & Other Practice Challenges
Improving reimbursement for underwater biosimilars is just one example of how the ACR’s practice advocates have achieved solutions to members’ insurance challenges. Here’s a look at current ACR efforts in insurance advocacy and how to get help with your own insurance challenges.
ACR Comments on 2025 Physician Fee Schedule
The ACR’s response to the Centers for Medicare & Medicaid Services addresses the likely harm of the proposed conversion factor on the solvency and stability of rheumatology practices. The comments also include recommendations on complex drug administration coding, inflation-adjusted drug rebates and extending telehealth flexibilities.
ACR-Led Coalition on Underwater Biosimilars Grows, Charts Next Steps
New members include rheumatology state societies, specialty partners in gastroenterology and patient-facing organizations representing digestive and inflammatory diseases. The ACR and coalition partners are strategizing additional steps to ensure practices receive adequate reimbursement for biosimilars.
Meet the ACR’s Advocacy Team
It’s an election year, and ACR staff are excited about the possibility of moving key initiatives, such as Medicare reimbursement, across the finish line. But they need members’ help to do so.
Government Affairs: A Marathon, Not a Sprint
Government Affairs Committee member Donald Miller, PharmD, reflects on the effects of rheumatology advocacy work over time, noting that progress is often easier to see from the distance.
ACR Delegation to Lead Several Resolutions at June AMA House of Delegates Meeting
The ACR will lead five other specialty societies on a resolution supporting pediatric specialty care and will co-lead resolutions addressing Medicare Advantage Part B drug coverage, white bagging mandates, state prescription drug affordability boards and impacts of alternative funding programs on access to care.
FTC Bans Noncompete Agreements: What Rheumatologists Need to Know
The ACR applauds the FTC’s recent ban on most noncompete agreements. The ruling is a step in the right direction toward a more competitive market for healthcare workers and their services.
Commercial Payers Update Reimbursement for Underwater Infliximab Biosimilars
Three commercial health insurance payers have increased reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »